Fluconazole alters the polysaccharide capsule of cryptococcus gattii and leads to distinct behaviors in murine cryptococcosis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Santos, Julliana Ribeiro Alves ^a   Holanda, Rodrigo Assunção ^a   Frases, Susana ^b,c   Bravim, Mayara ^b   Araujo, Glauber De S ^b,c   Santos, Patrícia Campi ^a   Costa, Marliete Carvalho ^a   Ribeiro, Maira Juliana Andrade ^a   Ferreira, Gabriella Freitas ^a   Baltazar, Ludmila Matos ^a   Miranda, Aline Silva ^a   Oliveira, Danilo Bretas ^a   Santos, Carolina Maria Araújo ^a   Fontes, Alide Caroline Lima ^a   Gouveia, Ludmila Ferreira ^a   Resende Stoianoff, Maria Aparecida ^a   Abrahão, Jonatas Santos ^a   Teixeira, Antonio Lúcio ^a   Paixão, Tatiane Alves ^a   Souza, Danielle G ^a   Santos, Daniel Assis ^a   more..

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; ERGOSTEROL; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; LACCASE; MULTIDRUG RESISTANCE PROTEIN 1; PEROXIDASE; POLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UREASE; ANTIFUNGAL AGENT; FUNGAL POLYSACCHARIDE;

AFR1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CAP59 GENE; CAP64 GENE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA SEQUENCE; DRUG SENSITIVITY; ENZYME ACTIVITY; ERG11 GENE; FUNGAL CAPSULE; FUNGAL GENE; FUNGAL STRAIN; FUNGAL STRUCTURES; FUNGAL VIRULENCE; GENE EXPRESSION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MACROPHAGE; MALE; MDR1 GENE; MENTAL HEALTH; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUSCLE STRENGTH; MUSCLE TONE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; REFLEX; SENSORIMOTOR FUNCTION; WEIGHT REDUCTION; ANIMAL; ANTIFUNGAL RESISTANCE; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIAL VIABILITY; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PATHOLOGY; PHENOTYPE; SEVERITY OF ILLNESS INDEX; SURVIVAL;

CRYPTOCOCCUS GATTII; MURINAE;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL CAPSULES; FUNGAL POLYSACCHARIDES; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROBIAL VIABILITY; PHENOTYPE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84911908514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112669     Document Type: Article

References (55)

1. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, et al. (2009) The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci USA 106 (31): 12980-12985.
2. Chen SC-A, Slavin MA, Heath CH, Playford EG, Byth K, et al. (2012) Clinical manifestations of Cryptococcus gattii infection: Determinants of neurological sequelae and death. Clin Infect Dis 55(6): 789-798.
3. Smith RM, Mba-Jonas A, Tourdjman M, Schimekm T, DeBess E, et al. (2014) Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest. Plos one 9(2): E88875. doi: 10.1371/journal.pone.0088875.
4. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 50: 291-322.
5. Gullo FP, Rossi SA, Sardi Jde CO, Teodoro VLI, Mendes-Giannini MJS, et al. (2013) Cryptococcosis: Epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis 32: 1377-1391.
6. Pfaller AM, Diekema DJ, Gibbs DL, Newell VA, Bijie H, et al. (2009) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 47: 117-123.
7. Fohrer C, Fornecker L, Nivoix Y, Cornila C, Marinescu C, et al. (2006) Antifungal combination treatment: A future perspective. Int J Antimicrob Agents 27: 25-30.
8. Santos JRA, Gouveia LF, Taylor ELS, Resende-Stoianoff MA, Pianetti GA, et al. (2012) Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother 56: 2553-2558.
9. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, et al. (1997) Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual frame-work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24: 235-247.
10. Alcazar-Fuoli L, Mellado E (2014) Current status of antifungal resistance and its impact on clinical practice. Br J Haematol. doi: 10.1111/bjh.12896.
11. Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd, ed. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Mendes FES, Oliveira LVN, Faria ES, Alvarenga DG, Pinto MR, et al. (2010) Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii. Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-010-1034-8.
13. Ferreira GF, Baltazar LM, Santos JRA, Monteiro AS, Fraga LAO, et al. (2013) The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii. J Antimicrob Chemother 68: 1801-1811.
14. Santos DA, Araú jo RAC, Hamdan JS, Cisalpino PS (2010) Trichophyton rubrum and Trichophyton interdigitale: Genetic diversity among species and strains by Random Amplified Polymorphic DNA Method. Mycopathologia 169: 247-55.
15. Saracli MA, Yildiran ST, Sener K, Gonlum A, Doganci L, et al. (2006) Genotyping of Turkish environmental Cryptococcus neoformans var. neoformans isolates by pulsed field gel electrophoresis and mating type. Mycoses 49(2): 124-129.
16. Chen YC, Eisner JD, Kattar MM, Rassoulian-Barrett SL, Lafe K, et al. (2001) Polymorphic internal transcribed spacer region 1 DNA sequences identify medically important yeasts. J Clin Microbiol 39: 4042-4051.
17. Rakeman JL, Bui U, Lafe K, Chen YC, Honeycutt RJ, et al. (2005) Multilocus DNA sequence comparisons rapidly identify pathogenic molds. J Clin Microbiol 43: 3324-3333.
18. Torres-Rodríguez JM, Alvarado-Ramírez E, Gutiérrez-Gallego R (2008) Diferencias en la actividad de la enzima ureasa entre Cryptococcus neoformans y Cryptococcus gattii. Rev Iberoam Micol 25: 27-31.
19. Alvarado-Ramírez E, Torres-Rodríguez JM, Sellart M, Vidotto V (2008) Laccase activity in Cryptococcus gattii strains isolated from goats. Rev Iberoam Micol 25: 150-153.
20. Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, et al. (2007) Selfaggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell 6: 1400-1410.
21. Bryan RA, Zaragoza O, Zhang T, Ortiz G, Casadevall E, et al. (2005) Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell 4: 465-475.
22. Casadevall A, Perfect JR (1998) Cryptococcus neoformans. J Antimicrob Chemother 44: 139.
23. Frases S, Pontes B, Nimrichter L, Rodrigues ML, Viana NB, et al. (2009) The elastic properties of the Cryptococcus neoformans capsule. Biophys J 97: 937-945.
24. Frases S, Nimrichter L, Viana NB, Nakouzi A, Casadevall A (2008) Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell 7(2): 319-327.
25. Maxeiner JH, Karwot K, Hausding M, Sauer KA, Scholtes P, et al. (2007) A method to enable the investigation of murine bronchial immune cells, their cytokines and mediators. Nat Protoc 2: 105-112.
26. Souza DG, Cara DC, Cassali GD, Coutinho SF, Silveira MR, et al. (2000) Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat. Br J Pharmacol 131: 1800-1808.
27. Lackner PR, Beer V, Heussler G, Goebel D, Rudzki R, et al. (2006) Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol 32: 177-188.
28. Pedroso VSP, Vilela MC, Santos PC, Cisalpino OS, Arantes RME, et al. (2010) Development of a murine model of neuroparacoccidioidomycosis. J Neuroparasitology 1: 39-44.
29. Khan ZU, Randhawa HS, Chehadeh W, Chowdhary A, Kowshik T, et al. (2009) Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole. Int J Antimicrob Agents 33: 559-563.
30. Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, et al. (2012) Cryptococcus neoformans- Cryptococcus gattii species complex: An international study of wild-Type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56: 5898-5906.
31. Matos CS, Andrade AS, Oliveira NS, Barros TF (2012) Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: Molecular types and antifungal susceptibilities. Eur J Clin Microbiol Infect Dis 31: 1647-1652.
32. Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, et al. (2007) Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 317: 916-924.
33. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ (2009) Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 53: 2804-2815.
34. Sionov E, Lee H, Chang YC, Kwon-Chung KJ (2010) Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6: E1000848. doi: 10.1371/journal.ppat.1000848.
35. Sionov E, Chang YC, Kwon-Chung KJ (2013) Azole heteroresistance in Cryptococcus neoformans: Emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob Agents Chemother 57: 5127-5130.
36. Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC (1998) Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42: 2584-2589.
37. Marr KA, Lyons CN, Ha K, Rustad TR, White TC (2001) Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 45: 52-59.
38. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, et al. (2011) In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var.grubii and Cryptococcus gattii serotype B from North-Western India. J Med Microbiol 60: 961-967.
39. Sanguinetti M, Posteraro B, La Sorda M, Torelli R, Fiori B, et al. (2006) Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect Immun 74: 1352-1359.
40. Joseph-Horne T, Hollomon D, Loeffler RS, Kelly SL (1995) Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 39: 1526-1529.
41. Gast C, Basso LR Jr, Bruzual I, Wong B (2013) Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11. Antimicrob Agents Chemother 57: 5478-5485.
42. Garcia-Rivera J, Chang YC, Kwon-Chung KJ, Casadevall A (2004) Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell 3: 385-392.
43. Moyrand F, Fontaine T, Janbon G (2007) Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence. Mol Microbiol 64: 771-781.
44. Chang YC, Penoyer LA, Kwon-Chung KJ (1996) The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 64: 1977-1983.
45. Wilder JA, Olson GK, Chang YC, Kwon-Chung, Lipscomb MF (2002) Complementation of a capsule deficient Cryptococcus neoformans with Cap64 restores virulence in a murine lung infection. Am J Respir Cell Mol Biol 26: 306-314.
46. Nosanchuk JD, Cleare W, Franzot SP, Casadevall A (1999) Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother 43: 233-239.
47. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, et al. (2008) Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol 10(10): 2043-2057.
48. Ngamskulrungroj P, Price J, Sorrell T, Perfect J, Meyer W (2011) Cryptococcus gattii virulence composite: Candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. Plos One 6(1): E16076.
49. Araujo GS, Fonseca FL, Pontes B, Torres A, Cordero RJB, et al. (2012) Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells. Plos One 7(1): E29561.
50. Johnston SA, May RC (2013) Cryptococcus interactions with macrophages: Evasion and manipulation of the phagosome by a fungal pathogen. Cell Microb 15: 403-411.
51. Cordero RJB, Pontes B, Guimarães AJ, Martinez LR, Rivera J, et al. (2011) Chronological aging is associated with capsule of cryptococcus neoformans biophysical and chemical changes in the Capsule of Cryptococcus neoformans. Infect Immun 79(12): 4990-5000.
52. Jain N, Fries BC (2009) Antigenic and phenotypic variations in fungi. Cell Microb 11: 1716-1723.
53. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux M-E, et al. (2007) Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 6(10): 1889-1904.
54. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC. Mol Microbiol 68(3): 624-641.
55. Pedroso VSP, Vilela MC, Santos PC, Cisalpino PS, Rachid MA, et al. (2013) Traffic of leukocytes and cytokine up-regulation in the central nervous system in a murine model of neuroparacoccidioidomycosis. Mycopathologia 176: 191-199.